Your session is about to expire
← Back to Search
Efgartigimod for Low Platelet Count (ADVANCE SC+ Trial)
ADVANCE SC+ Trial Summary
This trial will test the safety and effectiveness of a new drug, efgartigimod PH20, in adults with primary immune thrombocytopenia.
ADVANCE SC+ Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowADVANCE SC+ Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 3 trial • 110 Patients • NCT04735432ADVANCE SC+ Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am not taking any restricted medications like anti-CD20 therapy or live vaccines.I completed the 24-week ARGX-113-2004 trial.You are allergic to efgartigimod or any of its ingredients.I have completed a 52-week treatment period.
- Group 1: efgartigimod PH20 SC
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this the inaugural trial for this treatment?
"Research for efgartigimod PH20 SC started in 2020 with a study conducted and sponsored by argenx. Since the first Phase 3 trial in 2020, there have been 4 active studies involving this drug across 32 cities and 39 countries."
What is the most recent decision by the FDA on efgartigimod PH20 SC?
"While Phase 3 trials are not as conclusive as those in later stages, there is some evidence for efgartigimod PH20 SC's efficacy and multiple rounds of data supporting safety. As such, we've given it a score of 3."
Are there any other published papers that cite efgartigimod PH20 SC?
"efgartigimod PH20 SC was first studied in 2020 at Investigator Site 3800006. As of right now, there have been a total of 11 completed studies. There are 4 clinical trials recruiting patients at the moment, with a majority of these studies taking place in Bentonville, Arkansas."
Can patients still sign up for this experiment?
"This clinical trial, as reported on clinicaltrials.gov, is currently looking for candidates. The study was first posted on 11/17/2021 and was most recently updated on 6/27/2022."
How many participants will be included in this clinical trial?
"In order to move forward, this clinical trial requires 156 participants that match the pre-specified inclusion criteria. Patients have the opportunity to participate at various sites, such as Investigator Site 0010116 located in Bentonville, Arkansas or Investigator Site 0010095 situated in Oklahoma City, Oklahoma."
Share this study with friends
Copy Link
Messenger